Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors

被引：0
|
作者：
Heymach, John [1 ]
Yamamoto, Noboru [2 ]
Opdam, Frans [3 ]
Barve, Minal [4 ]
Tu, Hai-Yan [5 ]
Wu, Yi-Long [5 ]
Schroeter, Lukas [6 ]
Sadrolhefazi, Behbood [7 ]
Serra, Josep [8 ]
Yoh, Kiyotaka [9 ]
Berz, David [10 ]
机构：
[1] Univ Texas Houston, Dept Thorac Head & Neck Med Oncol, MD Anderson Canc Ctr, Div Canc Med, Houston, TX USA
[2] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[3] Netherlands Canc Inst, Dept Clin Pharmacol, Amsterdam, Netherlands
[4] Mary Crowley Canc Res, Dallas, TX USA
[5] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[7] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[8] 8 Boehringer Ingelheim Espana SA, Barcelona, Spain
[9] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[10] Valkyrie Clin Trials, Los Angeles, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA01.01
引用
收藏
页码：E1 / E1
页数：1
相关论文
共 50 条
  • [1] Beamion LUNG-1, a Phase Ia/Ib trial of the HER2-specific tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with HER2-driven tumors: outcomes according to HER2 aberration type
    Berz, D.
    Heymach, J.
    Opdam, F.
    Barve, M.
    Tu, H.
    Wu, Y.
    Mueller, A. M.
    Schroeter, L.
    Sadrolhefazi, B.
    Yoh, K.
    Yamamoto, N.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2024, 162 : S127 - S127
  • [2] Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data
    Heymach, John
    Opdam, Frans
    Barve, Minal A.
    Tu, Hai-Yan
    Wu, Yi-Long
    Berz, David
    Rohrbacher, Maren
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Yamamoto, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Beamion LUNG-1, a phase Ia/Ib trial of the HER2-specific tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with HER2driven tumours: outcomes according to HER2 aberration type in lung and other tumours
    Feuersinger, A.
    Opdam, F.
    Heymach, J.
    Barve, M.
    Tu, H.
    Wu, Y.
    Berz, D.
    Mueller, A. M.
    von Wangenheim, U.
    Serra, J.
    Yoh, K.
    Yamamoto, N.
    VIRCHOWS ARCHIV, 2024, 485 : S425 - S426
  • [4] Beamion Lung 1, a Phase Ia/Ib Trial of the HER2 TKI, BI 1810631 in Patients with Advanced Solid Tumors with HER2 Aberrations
    Yamamoto, N.
    Opdam, F.
    Barve, M.
    Tu, H. -Y.
    Wu, Y. -L.
    Schroeter, L.
    Sadrolhefazi, B.
    Serra, J.
    Yoh, K.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S147 - S147
  • [5] Phase Ia/Ib trial of the HER2 tyrosine kinase inhibitor zongertinib (BI 1810631) in patients with HER2-driven solid tumors: Focus on Asian patients
    Yoh, K.
    Opdam, F.
    Barve, M.
    Tu, H.
    Wu, Y-L.
    Berz, D.
    Schroeter, L.
    Sadrolhefazi, B.
    Serra, J.
    Heymach, J.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S1637 - S1638
  • [6] Primary Phase Ib Analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in Patients with HER2 Mutation-Positive NSCLC
    Ruiter, G.
    Tu, H. -Y.
    Ahn, M. -J.
    Yoh, K.
    Zugazagoitia, J.
    Smit, E.
    Wu, Y. -L.
    Planchard, D.
    Cho, B. -C.
    Wehler, B.
    Zhao, Y.
    von Wangenheim, U.
    Rohrbacher, M.
    Sadrolhefazi, B.
    Lin, G.
    Yu, Y.
    Nadal, E.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S4 - S5
  • [7] Zongertinib (BI 1810631) For HER2-Positive Solid Tumors with Brain Metastases: Subanalysis of the Beamion LUNG-1 Trial
    Opdam, F.
    Heymach, J. V.
    Berz, D.
    Barve, M.
    Tu, H. -Y.
    Wu, Y. -L.
    Schroeter, L.
    Serra, J.
    Sadrolhefazi, B.
    Yoh, K.
    Yamamoto, N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S105 - S105
  • [8] Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
    Opdam, F.
    Heymach, J.
    Ruiter, G.
    Barve, M.
    Tu, H.
    Wu, Y-L.
    Schroeter, L.
    Sadrolhefazi, B.
    Serra, J.
    Yoh, K.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2023, 34
  • [9] Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data.
    Heymach, John
    Opdam, Frans
    Barve, Minal A.
    Tu, Hai-Yan
    Wu, Yi-Long
    Berz, David
    Gibson, Neil
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Yamamoto, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Updated data from the Phase I Beamion Lung 1 trial of the HER2 tyrosine kinase inhibitor (TKI), BI 1810631, as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations
    Heymach, John
    Opdam, Frans
    Barve, Minal
    Tu, Hai-Yan
    Wu, Yi-Long
    Gibson, Neil
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Yamamoto, Noboru
    CANCER RESEARCH, 2023, 83 (08)
12345